GEN-MKT-18-7897-A
Aug 14, 2018 | Blogs, Clinical | 0 comments
According to the American Clinical Laboratory Association, more than 7 billion clinical lab tests are performed in the U.S. every year. While mass spectrometry represents only a fraction of the clinical applications, there are a growing number of tests where mass spectrometry is becoming the analytical method of choice. This is particularly the case where accuracy is challenged by interference from other compounds, such as toxicology testing, therapeutic drug monitoring, and in the measurement of low-level endogenous steroids.
This trend shift is driven by the analytical specificity of mass spectrometry as well as the advancement of this technology along with the development of new applications. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a particularly powerful, accurate, and robust technique for clinical diagnostics, especially for quantitative analysis of low concentration compounds. When comparing to conventional analytical techniques, the unique capabilities of mass spectrometry makes it is easy to see why mass spectrometry adoption is accelerating and beginning to play a prominent role in more areas of medicine.
As more labs make the move to mass spec, we look at the top five reasons why:
Clinical Mass Spec from SCIEX – Designed for Routine and Advanced DiagnosticsSCIEX In Vitro Diagnostic Medical Devices combine best-in-class mass spec instruments, intuitive software, and preconfigured methods*. Our solutions are fully backed by market leading service, support, and training to help guarantee your long-term success in adopting mass spec in your clinical lab. If you are:
Consider all the factors above, why is your lab waiting to save time, cut costs and support physicians with greater confidence and more accurate results? Learn More About How SCIEX Clinical Diagnostics Solutions Can Transform Your Clinical Lab >
SCIEX Diagnostics products are for in vitro diagnostic use. Product(s) may not be available in all countries. For information on availability, please contact your local representative. All other SCIEX products are for research use only. Not for use in diagnostic procedures.
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network